Combination therapy: The propitious rationale for drug development

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 1, 2014, Pages 53-67

  Phougat, Neetu ^a   Khatri, Savita ^a   Singh, Anu ^a   Dangi, Mrridula ^a   Kumar, Manish ^a   Dabur, Rajesh ^a   Chhillar, Anil Kumar ^a  

^a MAHARSHI DAYANAND UNIVERSITY   (India)

Author keywords

Antibiotics; Combination therapy; Drug; Resistance; Synergy; Therapeutics

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CEFDITOREN PIVOXIL; CEFOTAXIME; CEFTAROLINE FOSAMIL; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DAPTOMYCIN; DORIPENEM; ERTAPENEM; GEMIFLOXACIN; GENTAMICIN; LINEZOLID; MENHIBRIX; METICILLIN; NALIDIXIC ACID; NEW DRUG; PENICILLIN G; STREPTOMYCIN; TELAVANCIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SURVIVAL; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COMBINATION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PATENT; PENICILLIN RESISTANCE; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADAPTATION, PHYSIOLOGICAL; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL EVOLUTION; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS;

EID: 84893266738     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/13862073113166660065     Document Type: Article

References (138)

1. Bax, R.; Mullan, N.; Verhoef, J. The millennium bugs-the need for and development of new antibacterials. Int. J. Antimicrob. Agents, 2000, 16, 51-59.
2. Coates, A.; Hu, Y.; Bax, R.; Page, C. The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov., 2002, 1, 895-910.
3. Norrby, S.R.; Nord, C.E.; Finch, R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis., 2005, 5, 115-119.
4. Helen, W.B.; George H.T.; Daniel K.B.Jr.; John B.; Robert J.G.; Ronald N.J.; Barbara E.M.; Robert A.B.; David G. for the Infectious Diseases Society of America. 10 × '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America. Clin. Infect Dis., 2013, 56 (12), 1685-1694.
5. Hamel, J.C.; Stapert, D.; Moerman, J.K.; Ford, C.W. Linezolid, critical characteristics. Infection, 2000, 28(1), 60-64.
6. Jones, R.N.; Pfaller, M.A.; Jacobs, M.R.; Appelbaum, P.C.; Fuchs, P.C. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn. Microbiol. Infect. Dis., 2001, 41(1-2), 1-14.
7. Odenholt, I. Ertapenem: a new carbapenem. Expert Opin. Investig. Drugs, 2001, 10(6), 1157-1166.
8. Abbanat, D.; Macielag, M.; Bush, K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs, 2003, 12(3), 379-399.
9. Kirkpatrick, P.; Raja, A.; LaBonte, J.; Lebbos, J. Daptomycin. Nat. Rev. Drug Discov., 2003, 2(12), 943-944.
10. Scheinfeld, N. Telithromycin: a brief review of a new ketolide antibiotic. J. Drugs Dermatol., 2004, 3(4), 409-413.
11. Pankey, G.A. Tigecycline. J. Antimicrob. Chemother., 2005, 56(3), 470-80.
12. Matthews, S.J.; Lancaster, J.W. Doripenem monohydrate, a broadspectrum carbapenem antibiotic. Clin Ther., 2009, 31(1), 42-63.
13. Saravolatz, L.D.; Stein, G.E.; Johnson, L.B. Telavancin: a novel lipoglycopeptide. Clin. Infect. Dis., 2009, 49(12), 1908-1914.
14. Steed, M.E.; Rybak, M.J. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy, 2010, 30(4), 375-389.
15. Spellberg, B.; Blaser, M. Infectious Diseases Society of America (IDSA); Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis., 2011, 52(suppl 5), 397-428.
16. Bush, K.; Pucci, M.J. New antimicrobial agents on the horizon. Biochem. Pharmacol., 2011, 82, 1528-1539.
17. Perez, F.; Bonomo, R.A. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extendedspectrum β-lactamase-producing bacteria? Clin. Infect. Dis., 2012, 54, 175-177.
18. Grundmann, H.; Aires-de-Sousa, M.; Boyce, J.; Tiemersma, E. Emergence and resurgence of methicillin resistant Staphylococcus aureus as a public-health threat. Lancet, 2006, 368, 874-885.
19. File, T.M. Jr.; Tan, J.S.; Boex, J.R. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. Clin. Infect. Dis., 2006, 42, 798-800.
20. Sahm, D.F.; Benninger, M.S.; Evangelista, A.T.; Yee, Y.C.; Thornsberry, C. Brown NP. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005). Otolaryngol. Head Neck Surg., 2007, 136, 385-389.
21. Leavis, H.L.; Bonten, M.J.; Willems, R.J. Identification of highrisk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr. Opin. Microbiol., 2006, 9, 454-460.
22. Butler, D. New fronts in an old war. Nature, 2000, 406, 670-672.
23. Ginsberg, A.M. Tuberculosis drug development: Progress, challenges, and the road ahead. Tuberculosis, 2010, 90, 162-167.
24. Cottarel, G.; Wierzbowski, J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol., 2007, 25,12, 547-555.
25. D'Costa, V.M.; McGrann, K.M.; Hughes, D.W.; Wright, G.D. Sampling the antibiotic resistome. Science, 2006, 311, 374-377.
26. Linares, J.F.; Gustafsson, I.; Baquero, F.; Martinez, J.L. Antibiotics as intermicrobial signaling agents instead of weapons. Proc. Natl. Acad. Sci. U S A, 2006, 103, 19484-19489.
27. Falkow, S.; Kennedy, D. Antibiotics, animals, and people-again! Science, 2001, 291, 397.
28. Ferber, D. Antibiotic resistance: livestock feed ban preserves drugs' power. Science, 2002, 295, 27-28.
29. Levy, S.B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med., 2004, 10 (Suppl. 12), S122-S129.
30. Robicsek, A.; Jacoby, G.A.; Hooper, D.C. The worldwide emergence of plasmid mediated quinolone resistance. Lancet Infect. Dis., 2006, 6, 629-640.
31. Yu, J.L.; Grinius, L.; Hooper, D.C. Nor A functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J. Bacteriol., 2002, 184, 1370-1377.
32. Fournier, B.; Hooper, D.C. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob. Agents Chemother., 1998, 42, 2109-2112.
33. Pieren, M.; Tigges, M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr. Opin. Pharmacol., 2012, 12, 551-555.
34. A 4-drug combination (Stribild) for HIV. Med. Lett. Drugs Ther., 2012, 54(1404), 95-96.
35. Goldenberg, M.M. Pharmaceutical approval update. P T., 2012, 37(9), 499-502.
36. Levin, B.R.; Rozen, D.E. Non-inherited antibiotic resistance. Nat. Rev. Microbiol., 2006, 4, 556-562.
37. Szomolay, B.; Klapper, I.; Dockery, J.; Stewart, P.S. Adaptive responses to antimicrobial agents in biofilms. Environ. Microbiol., 2005, 7, 1186-1191.
38. Bonhoeffer, S.; Lipsitch, M.; Levin, B.R. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 12106-12111.
39. Hancock, R. E. W. The end of an era? Nat. Rev. Drug Discov., 2007, 6, 26.
40. Katz, M. L.; Mueller, L. V.; Polyakov, M.; Weinstock, S. F. Where have all the antibiotic patents gone? Nat. Biotechnol., 2006, 24, 1529-1531.
41. Bush, K. The evoution of b-lactamases. In: Antibiotic Resistance: Origins, Evolution, Selection and Spread. Chadwick, D.J., Goode, J., Eds.; John Wiley & Sons, Ciba Foundation Symposium, 1997, Vol. 207, pp. 152-166.
42. Medeiros, A.A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clini. Infect. Dis., 1997, 24, S19-45.
43. Bush, K. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect., 2004, 10, 10-17.
44. Abraham, E.P.; Chain, E. An enzyme from bacteria able to destroy penicillin. Nature, 1940, 146, 837.
45. Davies, J.E. Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Foundation Symp., 1997, 207, 15-27; discussion 27-35.
46. Hiramatsu, K.; Cui, L.; Kuroda, M.; Ito, T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol., 2001, 9, 486-493.
47. Peterson, L.R. Quinolone resistance in clinical practice: occurrence and importance. In: Quinolone. Antimicrobial Agents, 2nd Ed.; Hooper, D.C., Wolfson, J.S. Eds.; American Society for Microbiology, Washington, DC, 1993, pp.119-137.
48. Lacey, R.W.; Mitchell, A.A. Gentamicin-resistant Staphylococcus aureus. Lancet, 1969, 2, 1425-1426.
49. Then, R.L.; Angehrn, P. Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob. Agents Chemother., 1982, 21, 711-717.
50. Knothe, H.; Shah, P.; Krcmery, V.; Antal, M.; Mitsuhashi, S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection, 1983, 11, 315-317.
51. Clemett, D.; Markham, A.; Linezolid. Drugs, 2000, 59, 815-827; discussion 828.
52. Bozdogan, B.; Appelbaum, P.C. Oxazolidinones, activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents, 2004, 23, 113-119.
53. Evans, M.E.; Feola, D.J.; Rapp, R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother., 1999, 33, 960-967.
54. Davies, J. Bacteria on the rampage. Nature, 1996, 383, 219-220.
55. Jacoby, G.A.; Archer, G.L. New mechanisms of resistance to antibacterial agents. N. Engl. J. Med., 1991, 324, 601-612.
56. Levy, S.B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother., 1992, 36, 695-703.
57. Paulsen, I.T.; Brown, M.H.; Skurray, R.A. Proton-dependent multidrug efflux systems. Microbiol. Rev., 1996, 60, 575-608.
58. Ross, J. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP binding transport super gene family. Mol. Microbiol., 1990, 4, 1207-1214.
59. Philippon, A.; Labia, R.; Jacoby, G. Extended spectrum β-lactamases. Antimicrob. Agents Chemother., 1985, 28, 302-307.
60. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature, 2000, 406, 475-481.
61. Shaw, K.J.; Rather, P.N.; Hare, S.R.; Miller, G.H. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev., 1993, 57, 138-163.
62. Hon, W.C.; McKay, G.A.; Thompson, P.R.; Sweet, R.M.; Yang, D.S.; Wright, G.D.; Berghuis, A.M. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell, 1997, 89, 887-895.
63. Bussiere, D.; Muchmore, S.W.; Dealwis, C.G.; Schluckebier, G.; Nienaber, V.L.; Edalji, R.P.; Walter, K.A.; Ladror, U.S.; Holzman, T.F.; Abad-Zapatero, C. Crystal structure of ErmC, an rRNA methyltransferase which mediates antibiotic resistance in bacteria. Biochemistry, 1998, 37, 7103-7112.
64. Walsh, C.; Fisher, S.L.; Park, I.S.; Prahalad, M.; Wu, Z. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol., 1996, 3, 21-28.
65. Bugg, T.D.; Wright, G.D.; Dutka-Malen, S.; Arthur, M.; Courvalin, P.; Walsh, C.T. Molecular basis for vancomycin resistance in Enterococcus faecium, BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry, 1991, 30, 10408-10415.
66. Liassine, N.; Auckenthaler, R.; Descombes, M.C.; Bes, M.; Vandenesch, F.; Etienne, J. Community-acquired methicillinresistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J. Clin. Microbiol., 2004, 42, 825-828.
67. Ecker, D. J. The Microbial Rosetta Stone Database: a compilation of global and emerging infectious microorganisms and bioterrorist threat agents. BMC Microbiol., 2005, 5, 19.
68. Demain, A. L.; Sanchez, S. Microbial drug discovery: 80 years of progress. J. Antibiot., 2009, 62, 5-16.
69. Porschen, R.K. Legionnaires' disease more on staining and isolation of Legionella pneumophila. N. Engl. J. Med., 1979, 300, 369-370.
70. Chen, S.C.; Gilbert, G.L. Cat scratch disease: past and present. J. Paediat. Child Health, 1994, 30, 467-469.
71. Marshall, B.J. The Campylobacter pylori story. Scand. J. Gastroenterol., 1988, 146(Suppl): 58-66.
72. Ronchetti, F.; Ronchetti, R.; Guglielmi, F. Detection of Chlamydia pneumoniae in cholesteatoma tissue: any pathogenetic role? Otol. Neurotol., 2003, 24, 353-357.
73. Little, C.S.; Hammond, C.J.; MacIntyre, A.; Balin, B.J.; Appelt, D.M. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/ c mice. Neurobiol. Aging, 2004, 25, 419-429.
74. Dalton, R. Genetic sleuths rush to identify anthrax strains in mail attacks. Nature, 2001, 413, 657-658.
75. Brook, I.; Elliott, T.B.; Pryor, H.I. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents, 2001, 18, 559-62.
76. Peck, C. Drug Development: Improving the Process. Food 4 Drug Law Journal, 1997, 52.
77. US Food and Drug Administration. Labeling requirements for systematic antibacterial drug products intended for human use. 21 CFR Part 201 Docket; 00N-146, 2003.
78. Keim, K.L.; Calcagno, J.; Leventer, S.M.; Harris, H.W. Unlocking the value of failed CNS trials. Curr. Drug Dis., 2003, 3, 29-33.
79. DiMasi, J.A. Risks in new drug development: Approval success rates for investigational drugs. Clin. Pharmacol. Ther., 2001, 69, 297-307.
80. Hackbarth, C.J.; Chen, D.Z.; Lewis, J.G. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother., 2002, 46, 2752-2764.
81. Payne, D.J.; Miller, W.H.; Berry, V. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother., 2002, 46, 3118-3124.
82. Levy, S.B. The Antibiotic Paradox: How The Misuse of Antibiotics Destroys Their Curative Powers. 2nd Ed. Perseus Publishing, Cambridge, MA, 2002, 18.
83. Projan, S.J.; Shlaes, D.M. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect., 2004, 10, 18-22.
84. US Food and Drug Administration, IDSA, / PhRma / FDA, Working Group Meeting 2002; November 19-20.
85. Shlaes, D.M.; Gerding, D.N.; John, J.F.; Jr, Craig, W.A.; Bornstein, D.L.; Duncan, R.A.; Eckman, M.R.; Farrer, W.E.; Greene, W.H.; Lorian, V.; Levy, S.; McGowan, J.E.Jr; Paul, S.M.; Ruskin, J.; Tenover, F.C.; Watanakunakorn, C. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis., 1997, 25, 583-599.
86. Witte, W. Medical consequences of antibiotic use in agriculture. Science, 1998, 279, 996-997.
87. Astrauskiene, D. Efficacy of empirically prescribed amoxicillin and amoxicillin + clavulanic acid in children's reactive arthritis: a randomised trial. Clin. Exp. Rheumatol., 2003, 21, 515-521.
88. Sánchez, N.A. New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. Clin. Pharmacokinet., 2005, 44, 1097-1115.
89. Burgess, D.S.; Hall, R.G.; Hardin, T.C. In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis., 2003, 46, 131-137.
90. Ellis, R.; Lancaster, D.J. Cephawhatchamacallums. N. Engl. J. Med., 1989, 320, 872.
91. Kang, J.; Wang, L.; Chen, X.L.; Triggle, D.J.; Rampe, D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Molec Pharmacol., 2001, 59, 122-126.
92. French, G. Safety and tolerability of linezolid. J. Antimicrob. 5 Chemother., 2003, 51, ii45-53.
93. Zhanel, G.G.; Walters, M.; Noreddin, A. The ketolides: a critical review. Drugs, 2002, 62, 1771-804.
94. Lambert, R.J. and Lambert, R. A model for the efficacy of combined inhibitors. J. Appl. Microbiol., 2003, 95, 734-743.
95. Berenbaum, M.C. A method for testing for synergy with any number of agents. J. Infect. Dis., 1978, 137, 122-130.
96. Hallander, H.O.; Dornbusch, K.; Gezelius, L.; Jacobson, K.; Karlsson, I. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob. Agents Chemother., 1982, 22, 743-752.
97. Boucher, A.N.; Tam, V.H. Mathematical formulation of additivity for antimicrobial agents. Diagn. Microbiol. Infect. Dis., 2006, 55, 319-325.
98. Loewe, S. Antagonism and antagonists. Pharmacol. Rev., 1957, 9, 237-242.
99. Tallarida, R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther., 2006, 319, 1-7.
100. Loewe, S. Die quantitativen Probleme der Pharmakologie. Ergebn. Physiol., 1928, 27, 47-187.
101. Bliss, C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol., 1939, 26, 585-615.
102. Berenbaum, M.C. The expected effect of combination agents: the general solution. J. Theor. Biol., 1985, 114, 413-431.
103. Greco, W.R.; Bravo, G.; Parsons, J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 1995, 47, 331-385.
104. Machado, S.G.; Robinson, G.A. A direct, general approach based on isobolograms for assessing the joint action of drugs in preclinical experiments. Stat. Med., 1994, 13, 2289-2309.
105. Keith, C.T.; Borisy, A.A.; Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov., 2005, 4, 71-78.
106. Zimmermann, G.R.; Lehar, J.; Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12, 34-42.
107. Gavigan, C.S.; Machado, S.G.; Dalton, J.P; Bell, A. Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob. Agents Chemother., 2001, 45, 3175-3181.
108. Larsen, R.A.; Bauer, M.; Thomas, A.M.; Graybill, J.R. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob. Agents Chemother., 2004, 48, 985-991.
109. Goeres, D.M.; Loetterle, L.R.; Hamilton, M.A.; Murga, R.; Kirby, D.W.; Donlan, R.M. Statistical assessment of a laboratory method for growing biofilms. Microbiology, 2005, 151, 757-762.
110. Yeh, P.; Tschumi, A.I.; Kishony, R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet., 2006, 38, 489-494.
111. Chait, R.; Craney, A.; Kishony, R. Antibiotic interactions that select against resistance. Nature, 2007, 446, 668-671.
112. Schmatz, D.; Friend, S. A simple recipe for drug interaction networks earns its stars. Nat. Genet., 2006, 38, 405-406.
113. Kauppi, A.M.; Nordfelth, R.; Uvell, H.; Wolf-Watz, H.; Elofsson, M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol., 2003, 10(3), 241-249.
114. Desroy, N.; Denis, A.; Oliveira, C.; Atamanyuk, D.; Briet, S.; Faivre, F.; LeFralliec, G.; Bonvin, Y.; Oxoby, M.; Escaich, S.; Floquet, S.; Drocourt, E.; Vongsouthi, V.; Durant, L.; Moreau, F.; Verhey, T.B.; Lee, T.W.; Junop, M.S.; Gerusz, V. Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence. J. Med. Chem., 2013, 28, 56(4), 1418-1430.
115. Girja, S.S.; David, N.K. phage-displayed combinatorial peptide libraries in fusion to β-lactamase as reporter for an accelerated clone screening: potential uses of selected enzyme-linked affinity reagents in downstream applications. Comb. Chem. High Throughput Screen., 2010, 13, 75-87.
116. Dongyu, S.; Joon J.; Thomas S.; Rush III.; Zangwei, X.; Michael, J.W.; Ekaterina, B.; Alan, N.; Ilona, K. Efficient identification of novel leads by dynamic focused screening: PDK1 case study. Comb. Chem. High Throughput Screen., 2010, 13, 16-26.
117. Chong, S.; Liang, Z.; Guoliang, Z.; Qin, M. Polymer membrane and cell models for drug discovery. Comb. Chem. High Throughput Screen., 2012, 15, 3-14.
118. National Institutes of Health. Study comparing the safety and efficacy of intravenous CXA-201 and intravenous levofloxacin in complicated urinary tract infection, including pyelonephritis.
119. National Institutes of Health. Safety and efficacy of intravenous CXA-201 and intravenous meropenem in complicated intraabdominal infections.
120. Citron, D.M.; Tyrrell, K.L.; Merriam, V.; Goldstein, E.J. In vitro activity of ceftazidime-NXL104 against 396 strains of betalactamase-producing anaerobes. Antimicrob. Agents Chemother., 2011, 55, 3616-3620.
121. Endimiani, A.; Hujer, K.M.; Hujer, A.M.; Pulse, M.E.; Weiss, W.J.; Bonomo, R.A. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2011, 55, 82-85.
122. Lagace-Wiens, P.R.; Tailor, F.; Simner, P.; Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extendedspectrum beta-lactamases and class C betalactamases. Antimicrob. Agents Chemother., 2011, 55, 2434-2437.
123. Levasseur, P.; Girard, A.M.; Claudon, M. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother., 2012, 56,1606-1608.
124. Livermore, D.M.; Mushtaq, S.; Warner, M. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemaseproducing Enterobacteriaceae. Antimicrob. Agents Chemother., 2011, 55, 390-394.
125. Mushtaq, S.; Warner, M.; Livermore, D.M. In vitro activity of ceftazidime +NXL104 against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother., 2010, 65, 2376-2381.
126. Walkty, A.; DeCorby, M.; Lagace-Wiens, P.R.; Karlowsky, J.A.; Hoban, D.J.; Zhanel, G.G. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother., 2011, 55, 2992-2994.
127. National Institutes of Health. Compare ceftazidime-avibactam + metronidazole versus meropenem for hospitalized adults with complicated intra-abd infections.
128. National Institutes of Health. Ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs (urinary tract infections).
129. National Institutes of Health. Ceftazidime-avibactam for the treatment of infections due to ceftazidime resistant pathogens.
130. Castanheira, M.; Sader, H.S.; Farrell, D.J.; Mendes, R.E.; Jones, R.N. Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types. Antimicrob. Agents Chemother., 2012, 56, 4779-4785.
131. Wiskirchen, D.E.; Crandon, J.L.; Furtado, G.H.; Williams, G.; Nicolau, D.P. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrumbeta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother., 2011, 55, 3220-3225.
132. Hirsch, E.B.; Ledesma, K.R.; Chang, K.T.; Schwartz, M.S.; Motyl, M.R.; Tam, V.H. In vitro activity of MK-7655, a novel betalactamase inhibitor, in combination with imipenem against carbapenem-resistant gramnegative bacteria. Antimicrob. Agents Chemother., 2012, 56, 3753-3757.
133. National Institutes of Health. Study of the safety, tolerability, and efficacy of MK-7655 + imipenem/cilastatin vs imipenem/cilastatin alone for the treatment of complicated urinary tract infection (cUTI) (MK-7655-003 AM2).
134. National Institutes of Health. Study of the safety, tolerability, and efficacy of MK-7655 + imipenem/cilastatin versus imipenem/cilastatin alone to treat complicated intra-abdominal infection [cIAI] (MK-7655-004 AM2).
135. Nathan, C. Antibiotics at the crossroads. Nature, 2004, 431, 899-902.
136. Mukherjee, P.K.; Sheehan, D.J.; Hitchcock, C.A.; Ghannoum, M.A. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev., 2005, 18, 163-194.
137. Ruhil, S.; Balhara, M.; Dhankhar, S.; Kumar, M.; Kumar, V.; Chhillar, A.K. Advancement in infection control of opportunistic pathogen (Aspergillus spp.): Adjunctive agents. Curr. Pharmaceut. Biotechnol., 2012, 14 (2), 226-232.
138. Owens, R. C. Jr.; Ambrose, P.G. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis., 2005, 41 (Suppl. 2), S144-S157.